XM does not provide services to residents of the United States of America.
M
M

Morphosys

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Morphosys Announces Voluntary Delisting From The Nasdaq Global Market

BRIEF-Morphosys Announces Voluntary Delisting From The Nasdaq Global Market July 12 (Reuters) - MorphoSys AG MORG.DE : EQS-NEWS: MORPHOSYS ANNOUNCES VOLUNTARY DELISTING FROM THE NASDAQ GLOBAL MARKET MORPHOSYS AG - EXPECTS THAT LAST TRADING DAY ON NASDAQ WILL BE ON OR ABOUT AUGUST 2, 2024 Source text for Eikon: ID:nEQ1B29X1a Further company coverage
M

Morphosys Says Merger Squeeze-Out Cash Compensation Determined At Eur 68.00

BRIEF-Morphosys Says Merger Squeeze-Out Cash Compensation Determined At Eur 68.00 July 12 (Reuters) - MORPHOSYS AG MORG.DE : MERGER SQUEEZE-OUT CASH COMPENSATION DETERMINED AT EUR 68.00 ANNOUNCES THAT NOVARTIS BIDCO GERMANY AG SUBMITTED A SPECIFIED REQUEST (KONKRETISIERTES VERLANGEN) TO MORPHOSYS AG MANAGEMENT BOARD COURT-APPOINTED EXPERT AUDITOR H
M

Morphosys And Novartis Sign Delisting Agreement

BRIEF-Morphosys And Novartis Sign Delisting Agreement June 20 (Reuters) - MORPHOSYS AG MORG.DE : MORPHOSYS AND NOVARTIS SIGN DELISTING AGREEMENT AND INTEND TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS’ MINORITY SHAREHOLDERS MORPHOSYS AG - ACCEPTANCE PERIOD OF TAKEOVER OFFER AND STATUTORY TWO-WEEK ADDITIONAL ACCEPTANCE PERIOD ENDED ON MAY 13, 20
M
N

Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders

BRIEF-Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders June 20 (Reuters) - MORPHOSYS AG MORG.DE : NOVARTIS BIDCO GERMANY AG INTENDS TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS AG’S MINORITY SHAREHOLDERS NOVARTIS BIDCO GERMANY AG CONFIRMED THAT IT CURRENTLY HOLDS APPROXIMATELY 91.04% OF TOTAL MORPHOSYS AG SHARE
M
N

Morphosys: Pichota and Lukas Gilgen replacing CEO And CFO

BRIEF-Morphosys: Pichota and Lukas Gilgen replacing CEO And CFO June 7 (Reuters) - MORPHOSYS AG MORG.DE : EQS-ADHOC: AD HOC: ARKADIUS PICHOTA AND LUKAS GILGEN APPOINTED TO MANAGEMENT BOARD OF MORPHOSYS AG REPLACING THE CURRENT CEO AND CFO Source text for Eikon: ID:nEQQh9gja Further company coverage: MORG.DE (Gdansk Newsroom)
M

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.